Bio-Rad Q1 revenue $700.1M (-3.7% YoY); core ex-COVID up 6.5%; non-GAAP EPS $4.94 vs $5.21

BIO-RAD LABORATORIES, INC.

2022-Q1 EPS reported -$112.57 revenue$700,062,000

GAAP net loss $3.37B from Sartorius fair value change; non-GAAP net income $149.1M.
Life Science segment sales $347.2M (-5.3% YoY); Clinical Diagnostics $351.8M (-1.9%).
Full-year 2022 outlook: non-GAAP currency-neutral revenue growth ~1-2%; op margin ~19%.
COVID-related revenue fell to ~$45M vs $94M in Q1 2021; core business grew 6.5% currency-neutral.
Management notes macro risks: China lockdowns, Ukraine war, supply chain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.